personalized medicine
23andMe Gets $50M Payment as GSK Extends Companies' Drug Discovery Alliance
The companies are using 23andMe's extensive genotype-phenotype database and other resources to identify targets for personalized therapeutics, continuing an alliance begun in 2018.
Multiomic Profiling Uncovers Predictors of Melanoma Response to Immunotherapy
A model based on the results could predict treatment response but was less able to forecast resistance, suggesting heterogeneous mechanisms.
Breast Cancer Therapy Response Predicted by Multiomic Machine Learning Model
A team led by researchers at the University of Cambridge analyzed more than 160 pre-treatment tumor biopsies to identify features linked to treatment response.
Redx Pharma, Caris Life Sciences Partner for Colorectal Cancer Phase II Drug Study Recruitment
The pharma firm is using Caris’ comprehensive molecular profiling to help advance its investigational Porcupine inhibitor, RXC004, in the US.
GE Healthcare, University of Cambridge Team on AI-Based Precision Oncology
Building on earlier work supported by the Mark Foundation for Cancer Research and Cancer Research UK, the partners will create an app to aggregate and analyze clinical, genomic, and imaging data.